EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

SPOTLIGHT: A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihis

Sunday 02 Jun, 12:00 PM - 12:00 PM Valencia, Spain